Hursting M J, Butman B T, Steiner J P, Moore B M, Plank M C, Szewczyk K M, Bell M L, Dombrose F A
Organon Teknika Corp., Durham, NC 27704.
Clin Chem. 1993 Apr;39(4):583-91.
Prothrombin fragment 1.2 (F1.2) is an activation peptide generated during a critical event of blood coagulation, the conversion of prothrombin to thrombin. As a marker of thrombin generation, F1.2 has clinical potential in assessing thrombotic risk and monitoring anticoagulant therapy. In developing a highly specific, monoclonal antibody-based immunoassay of human plasma F1.2, we generated six murine anti-F1.2 monoclonal antibodies, using as immunogen a synthetic peptide (sequence: CGSD-RAIEGR) similar to the unique carboxyl terminus of F1.2. Each antibody bound F1.2 but not prothrombin. Epitope mapping studies with one antibody (5-3B) showed that optimum binding required six to eight amino acids plus a terminal arginine to emulate the F1.2 carboxyl terminus. A quantitative sandwich ELISA for human plasma F1.2 was configured with monoclonal antibody 5-3B as the capture antibody and peroxidase-labeled polyclonal antibodies to the F1.2 amino-terminal region as detector antibodies. Calibrators were prepared by adding purified F1.2, 0-10 nmol/L, to F1.2-depleted plasma. Assay characteristics included the following: mean (+/- SD) analytical recovery of 98% +/- 13%; no interference from lipemia, hemolysis, icterus, or thrombolytic agents; 0.08 nmol/L sensitivity; and mean intra- and interassay imprecision (three lots) < 12% at both low and high concentrations of F1.2.
凝血酶原片段1.2(F1.2)是血液凝固关键事件——凝血酶原转化为凝血酶过程中产生的一种激活肽。作为凝血酶生成的标志物,F1.2在评估血栓形成风险和监测抗凝治疗方面具有临床应用潜力。在开发一种基于单克隆抗体的高特异性人血浆F1.2免疫测定方法时,我们使用一种与F1.2独特羧基末端相似的合成肽(序列:CGSD - RAIEGR)作为免疫原,制备了六种鼠抗F1.2单克隆抗体。每种抗体均能结合F1.2而不结合凝血酶原。对一种抗体(5 - 3B)进行的表位作图研究表明,最佳结合需要六到八个氨基酸加上一个末端精氨酸来模拟F1.2的羧基末端。以单克隆抗体5 - 3B作为捕获抗体,以过氧化物酶标记的针对F1.2氨基末端区域的多克隆抗体作为检测抗体,构建了一种用于人血浆F1.2的定量夹心ELISA。通过向去除F1.2的血浆中添加0 - 10 nmol/L的纯化F1.2来制备校准品。该测定方法的特性如下:平均(±标准差)分析回收率为98%±13%;不受脂血、溶血、黄疸或溶栓剂的干扰;灵敏度为0.08 nmol/L;在低浓度和高浓度F1.2时,平均批内和批间不精密度(三个批次)均<12%。